Literature DB >> 9369421

Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia.

F Lacombe1, F Durrieu, A Briais, P Dumain, F Belloc, E Bascans, J Reiffers, M R Boisseau, P Bernard.   

Abstract

A flow cytometry method has been introduced into the routine investigation of whole bone marrow samples following red blood cell lysis on the basis of a primary CD45/side scatter (SSC) gating procedure. Blast cells were first identified by CD45/SSC gating in 74 cases of acute myeloid leukemia (AML) and the results were compared to a conventional FSC/SSC gating procedure and to MGG-staining smears. The percentages of blast cells in these samples as defined by the morphological analysis of MGG smears correlated better with the values determined by CD45/SSC gating (r = 0.94) than with the blast cell counts recorded with FSC/SSC gating (r = 0.76). These findings were not surprising because while CD45 expression was regularly lower on leukemic blasts than on normal lymphoid and monocytic cells, the FCS/SSC characteristics of these populations were overlapping. In 53 samples, the blast cell populations were also analyzed with a panel of FITC-conjugated monoclonal antibodies that were utilized in double labeling with CD45-PE. We show that the CD45/SSC gating procedure improved phenotypic determination of the blast cells in three ways: (1) by discriminating between leukemic blast cells and residual normal cells; (2) by excluding normal cells from the phenotypic analysis of leukemic blast cells; and (3) by identifying blast cell heterogeneity in many cases of leukemia on the basis of different CD45 display. Moreover, this immunophenotyping procedure on whole bone marrow samples also allowed an efficient discrimination between the various cell lineages and facilitated the analysis of leukemic blasts present in low proportions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369421     DOI: 10.1038/sj.leu.2400847

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  44 in total

1.  Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.

Authors:  Corine J Hess; Nicole Feller; Fedor Denkers; Angèle Kelder; Pauline A Merle; Michael C Heinrich; Amy Harlow; Johannes Berkhof; Gert J Ossenkoppele; Quinten Waisfisz; Gerrit J Schuurhuis
Journal:  Haematologica       Date:  2008-11-27       Impact factor: 9.941

2.  EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes.

Authors:  J J M van Dongen; L Lhermitte; S Böttcher; J Almeida; V H J van der Velden; J Flores-Montero; A Rawstron; V Asnafi; Q Lécrevisse; P Lucio; E Mejstrikova; T Szczepański; T Kalina; R de Tute; M Brüggemann; L Sedek; M Cullen; A W Langerak; A Mendonça; E Macintyre; M Martin-Ayuso; O Hrusak; M B Vidriales; A Orfao
Journal:  Leukemia       Date:  2012-05-03       Impact factor: 11.528

3.  Evaluation of a multicolor, single-tube technique to enumerate lymphocyte subpopulations.

Authors:  F Colombo; A Cattaneo; R Lopa; P Portararo; P Rebulla; L Porretti
Journal:  Clin Vaccine Immunol       Date:  2008-04-30

4.  Deep profiling of multitube flow cytometry data.

Authors:  Kieran O'Neill; Nima Aghaeepour; Jeremy Parker; Donna Hogge; Aly Karsan; Bakul Dalal; Ryan R Brinkman
Journal:  Bioinformatics       Date:  2015-01-18       Impact factor: 6.937

5.  CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease.

Authors:  Francesco Mannelli; Giacomo Gianfaldoni; Tamara Intermesoli; Chiara Cattaneo; Erika Borlenghi; Sergio Cortelazzo; Irene Cavattoni; Enrico Maria Pogliani; Monica Fumagalli; Emanuele Angelucci; Claudio Romani; Fabio Ciceri; Consuelo Corti; Anna Scattolin; Agostino Cortelezzi; Daniele Mattei; Ernesta Audisio; Orietta Spinelli; Elena Oldani; Alberto Bosi; Alessandro Rambaldi; Renato Bassan
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

6.  Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML.

Authors:  Thanh-Trang Vo; Jeremy Ryan; Ruben Carrasco; Donna Neuberg; Derrick J Rossi; Richard M Stone; Daniel J Deangelo; Mark G Frattini; Anthony Letai
Journal:  Cell       Date:  2012-10-12       Impact factor: 41.582

7.  Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.

Authors:  S A Bright; A M McElligott; J W O'Connell; L O'Connor; P Carroll; G Campiani; M W Deininger; E Conneally; M Lawler; D C Williams; D M Zisterer
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

8.  Prognostic significance of flow cytometric immunophenotyping in acute myeloid leukemia.

Authors:  Brian A Webber; Melissa M Cushing; Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

9.  The cyclin-dependent kinase inhibitor 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole induces nongenotoxic, DNA replication-independent apoptosis of normal and leukemic cells, regardless of their p53 status.

Authors:  Valentina Turinetto; Paola Porcedda; Luca Orlando; Mario De Marchi; Antonio Amoroso; Claudia Giachino
Journal:  BMC Cancer       Date:  2009-08-12       Impact factor: 4.430

10.  FlowFP: A Bioconductor Package for Fingerprinting Flow Cytometric Data.

Authors:  Wade T Rogers; Herbert A Holyst
Journal:  Adv Bioinformatics       Date:  2009-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.